LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial

Peter A. Fasching, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, John Crown, Amit Bardia, S. Chia, S-A Im, M. Martín Jiménez, B. Xu, Sherene Loi, Carlos H. Barrios, M. Untch, R Moroose, F. Visco, Gabriel N. Hortobágyi, Dennis J. Slamon, Yisel Meza Oviedo, Simon Waters, S.A. Hurvitz